Published online Nov 18, 2021. doi: 10.5312/wjo.v12.i11.877
Peer-review started: May 4, 2021
First decision: June 7, 2021
Revised: June 27, 2021
Accepted: September 14, 2021
Article in press: September 14, 2021
Published online: November 18, 2021
Processing time: 195 Days and 9.9 Hours
Total hip arthroplasty (THA) is an effective treatment for most patients who suffer from pain and decreased functional ability due to hip osteoarthritis (OA). The main risk factors for developing hip OA are advanced age, family history of OA, previous hip injury, hip dysplasia, and obesity. The increased prevalence of obesity has resulted in orthopedic surgeons being likely to face many patients with a high body mass index (BMI) who warrant THAs over the coming years. On the other hand, there has been growing interest in the direct anterior approach (DAA) in recent years because of its soft-tissue–preserving nature. Total hip arthroplasty (THA) is an effective treatment for most patients who suffer from pain and decreased functional ability due to hip osteoarthritis (OA). The main risk factors for developing hip OA are advanced age, family history of OA, previous hip injury, hip dysplasia, and obesity. The increased prevalence of obesity has resulted in orthopedic surgeons being likely to face many patients with a high body mass index (BMI) who warrant THAs over the coming years. On the other hand, there has been growing interest in the direct anterior approach (DAA) in recent years because of its soft-tissue–preserving nature.
In the literature, it has been reported that obesity is significantly associated with a greater need for joint replacement and that compared to patients with normal body mass index (BMI), obese patients may require a THA up to ten years earlier. Some studies indicate that obesity is associated with poorer clinical, functional outcomes, while others have shown that obese patients do not differ from the nonobese in this respect. The data are considered controversial, and further studies need to be performed on obese patients, especially comparative evaluations that compare minimally invasive techniques such as DAA with classical surgical techniques, such as the Hardinge approach. Compared to other classical surgical approaches used in obese patients, the Hardinge was chosen because it offers better access to the hip joint and achieves a lower dislocation rate by preserving its posterior stabilizer muscles.
We aimed to compare DAA and Hardinge in hip OA patients who have undergone primary THA regarding postoperative pain levels, functional status, and quality-of-life. In addition, it was investigated whether these parameters differ between obese and nonobese patients.
The present study was a prospective, four-group randomized controlled trial (Clinical Trial Identifier: ISRCTN15066737). One hundred twenty participants were divided into four groups (30 patients per group) according to both the surgical approach used and their body mass index (BMI) as follow: DAA-nonobese group (BMI < 30 kg/m2), DAA-obese group (BMI ≥ 30 kg/m2), Harginge-nonobese group (BMI < 30 kg/m2) and Harginge-obese group (BMI ≥ 30 kg/m2). Measurements were carried out prior to surgery (baseline) and postoperatively (at the end of the 6th week and 12th week). Pain levels were measured with the Face Pain Scale – Revised (FPS-R). Functional ability was evaluated with the Timed Up & Go (TUG) test and the Greek version of the Modified Harris Hip Score (MHHS-Gr). Quality-of-life was measured with the Greek version of the International Hip Outcome Tool -12 items (iHOT12-Gr).
DAA vs Hardinge regardless of BMI: The DAA resulted in less postoperative pain and offered faster and increased functional ability and better quality-of-life than the Hardinge. DAA-nonobese vs Hardinge-nonobese: The DAA leads faster to better functional ability and quality-of-life compared to the Hardinge in nonobese patients. DAA-obese vs Hardinge-obese: DAA leads faster to better functional ability and quality-of-life of obese patients than the Hardinge; at 12 wk, statistically significant differences between groups were narrowed. Nonobese vs obese regardless of surgical approach: the only statistically significant difference between obese and nonobese patients was revealed in the self-reported functional ability. DAA-nonobese vs DAA-obese: no statistically significant differences were observed in comparing postoperative outcomes. The DAA similarly benefited both obese and nonobese patients. Hardinge-nonobese vs Hardinge-obese: Hardinge-nonobese reached higher functionality than Hardinge-obese patients.
DAA patients reported less pain, more functionality, and quality-of-life improvements compared to the Hardinge. Moreover, DAA exhibits equivalent postoperative outcomes in obese and nonobese patients, suggesting a better-suited THA surgical approach for patients with increased BMI.
Further research based on well-designed studies with longer follow-up and larger samples need to be performed to elucidate the efficacy of DAA on functionality and quality of life of hip OA obese patients.